艾司氯胺酮对比替代策略治疗难治性抑郁的成本效果:香港多臂建模研究
该研究用马尔可夫队列模型模拟香港成人难治性抑郁患者5年内的转归,比较艾司氯胺酮联合抗抑郁药与六种三线策略的成本效果。结果显示艾司氯胺酮相对rTMS和ECT更具成本效果,但相对增效、联合、心理治疗等策略不具成本效果。
要点
- 艾司氯胺酮相对rTMS(被支配)和ECT(ICER US$322,407/QALY)更具成本效果。
- 艾司氯胺酮相对增效、联合、心理治疗等策略的ICER为US$134,127–312,750/QALY,不具成本效果。
- 联合治疗在所有评估策略中成本效果最优。
核心结论
- 艾司氯胺酮相对rTMS和ECT更具成本效果,但相对其他常用三线策略不具成本效果。
- 联合治疗在所有评估策略中成本效果最优。
研究设计与样本
- 马尔可夫队列模型模拟香港成人难治性抑郁患者,时间跨度5年,周期4周。
- 比较艾司氯胺酮联合抗抑郁药与六种三线策略:联合治疗、增效治疗、单用心理治疗、心理治疗联合抗抑郁药、rTMS联合抗抑郁药、ECT联合抗抑郁药。
- 主要结局为QALYs和增量成本效果比(ICER),支付意愿阈值US$50,000/QALY。
- 开展确定性、概率敏感性分析和情景分析,聚焦替代给药方案、服务提供策略及与其他治疗比较。
主要发现
- 基础分析中,艾司氯胺酮相对增效、联合、心理治疗或心理治疗联合抗抑郁药的ICER为US$134,127至US$312,750/QALY。
- 艾司氯胺酮相对rTMS被支配,相对ECT的ICER为US$322,407/QALY。
- 联合治疗在所有评估策略中成本效果最优。
关键数值与推荐
- 难治性抑郁定义为至少两种足量抗抑郁药方案治疗失败。
- 支付意愿阈值US$50,000/QALY。
- 艾司氯胺酮相对增效、联合、心理治疗或心理治疗联合抗抑郁药的ICER为US$134,127至US$312,750/QALY。
- 艾司氯胺酮相对ECT的ICER为US$322,407/QALY。
临床怎么用
- 成本效果证据可帮助在传统治疗线框架之外制定更贴合情境的治疗顺序策略。
- 价格谈判、优化服务提供和替代给药策略可能提升艾司氯胺酮治疗难治性抑郁的价值。
局限性
- 依赖间接比较和来自异质性临床试验人群的假设,可能不完全反映真实世界患者特征和治疗路径。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Treatment-resistant depression (TRD), defined as failure to respond to at least two adequately administered antidepressant (AD) regimens, imposes major clinical and economic burdens. Esketamine nasal spray offers rapid antidepressant clinical effects, yet previous evaluations compared it only with unrealistic comparators such as AD monotherapy. This study assessed the cost-effectiveness of esketamine versus multiple alternative third-line strategies for TRD from the Hong Kong healthcare payer's perspective. METHODS AND FINDINGS: A Markov cohort model simulated adults with TRD in Hong Kong over 5 years with 4-week cycles. The model compared esketamine plus AD with six alternative third-line treatment strategies: combination therapy (AD plus AD), augmentation therapy (AD plus antipsychotic or lithium), psychotherapy alone, psychotherapy plus AD, repetitive transcranial magnetic stimulation (rTMS) plus AD, and electroconvulsive therapy (ECT) plus AD. Primary outcomes were quality-adjusted life-years (QALYs) and incremental cost-effectiveness ratios (ICERs) under a US$50,000/QALY willingness-to-pay (WTP) threshold. Deterministic and probabilistic sensitivity analyses and scenario analyses were conducted, focusing on alternative esketamine dosing, delivery strategies, and comparisons with other treatment options to assess the robustness of the results. In base-case analysis, esketamine was not cost-effective versus augmentation, combination, psychotherapy, or psychotherapy plus AD with ICERs ranging from US$134,127 to US$312,750 per QALY but was more cost-effective than rTMS (dominated) and ECT (ICER: US$322,407/QALY). Combination therapy was the most cost-effective among all strategies evaluated. The main limitation of this study is the reliance on indirect comparisons and assumptions derived from heterogeneous clinical trial populations, which may not fully reflect real-world patient characteristics and treatment pathways. CONCLUSIONS: Esketamine appeared more cost-effective than rTMS and ECT, but not cost-effective compared with other commonly used third-line treatment strategies for TRD. These findings suggest that cost-effectiveness evidence may help inform more context-sensitive treatment sequencing strategies beyond conventional line-of-therapy frameworks. Policy approaches such as price negotiation, optimized service delivery, and alternative dosing strategies may improve the value of esketamine for TRD management.
引用
- Li Y, Chan VKY, Jit M, et al. Cost-effectiveness of esketamine versus alternative treatment strategies for treatment-resistant depression in Hong Kong: A multi-armed modeling study. PLoS Med. 2026. PMID: 41990095. doi:10.1371/journal.pmed.1005047
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。